Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netarsudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 19/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 6/20 | 1.00 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netarsudil SCHEMBL114266 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL21679903 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29478436 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL16036278 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL16037348 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29673273 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29677622 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL113753 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL113752 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL114348 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1057 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102187-A1 | ENGINEERED VIRUS-LIKE PARTICLES COMPRISING A BASE EDITOR FOR THE TREATMENT OF GLAUCOMA, AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090172-A1 | CELL CULTURE SYSTEMS COMPRISING MICROPATTERNED ARRAYS AND METHODS OF USE | ALTIS BIOSYSTEMS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| EP-4005574-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA | Universidade de Santiago de Compostela (ES) | 2022-06-01 | — | — | EP | claimed |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | Micro Labs Ltd. (IN) | 2022-05-31 | — | — | US | claimed |
| CN-114540278-A | Microvessel in-vitro culture method and culture solution | 青岛大学 | 2022-05-27 | — | — | CN | claimed |
| US-11337985-B2 | Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of L-DOPA-induced dyskinesia | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-05-24 | — | — | US | claimed |
| CN-114467915-A | Cryopreservation solution for primary tumor cells and/or cell spheroid | 广州市达瑞生物技术股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114401725-A | Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of levodopa-induced dyskinesia | 圣地亚哥德·冈波忒拉大学 | 2022-04-26 | — | — | CN | claimed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | claimed |
| WO-2022066772-A1 | RAFT CULTURES AND METHODS OF MAKING THEREOF | CHILDREN´S HOSPITAL MEDICAL CENTER (US) | 2022-03-31 | — | — | WO | claimed |
| EP-3946268-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | The Regents of The University of California (US) | 2022-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | SGMS2, SGMS1, LIPA | ROCK2 1012/4885ROCK1 1276/4885MYLK4 2004/4885 |
| US-20260137558-A1 | OPHTHALMIC DEVICE | IL2, ICOS, TRHDE | ROCK2 171/4885ROCK1 526/4885MYLK4 1372/4885 |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | VKORC1L1, CYP3A4, REN | ROCK2 165/4885ROCK1 52/4885MYLK4 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.